Clinical Trials Browser

INDUSTRY × Hematologic Neoplasms × elotuzumab × Clear all

NCT00742560 2018-01-10

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Phase 2 Completed

101 enrolled 20 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms